Drug profile · INN
mecasermin rinfabate recombinant
IPLEX
mecasermin rinfabate recombinant (IPLEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — mecasermin rinfabate recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
mecasermin rinfabate recombinant (IPLEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin-like growth factor I receptor agonist
Primary target: Insulin-like growth factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mecasermin rinfabate recombinant?
mecasermin rinfabate recombinant (IPLEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mecasermin rinfabate recombinant?
IPLEX is a marketed brand name for mecasermin rinfabate recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mecasermin rinfabate recombinant?
mecasermin rinfabate recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.